Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC — Stella

Recruiting

Back to Non-small Cell Lung Cancer trials

Trial locations(1 site)

China

Yongchang Zhang, Changsha, Hunan

Key details

Sponsor

Hunan Province Tumor Hospital

Enrollment target

~800 participants

Started

March 2020

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov